Express Pharma
Home  »  Market  »  IPM registers Rs 7917 crores in March 2016

IPM registers Rs 7917 crores in March 2016

Read Article

South Rajasthan grew the highest followed by Chattisgarh and Haryana

The Indian Pharmaceutical Market (IPM) has clocked Rs 7917 crores in March 2016, growing at 6.4 per cent. Amongst the top 10 corporates, Lupin grew by 20.6 per cent, Sun by 12.3 per cent and Mankind at 11.9 per cent. 23 corporates have crossed the growth of IPM amongst top 50. Amongst the top 50 corporates, Janssen had the highest growth of 26 per cent followed by Bharat Serums at 25.8 per cent and Allergan at 25.4 per cent. 16 corporates have shown growths of more than 10 per cent amongst the top 50. Amongst the 11-20 ranked corporates, Intas had the highest growth of 16.2 per cent followed by Micro at 12 per cent and USV at 11.3 per cent. Amongst the 21-30 ranked corporates, Novartis had the highest growth at 14.1 per cent followed by Cadila at 7.2 per cent and Eris at 5.5 per cent. Amongst the 31-40 ranked dorporates, Bharat Serums grew at 25.8 per cent followed by Wallace at 16.4 per cent and JBCPL at 11.5 per cent. Amongst the 41-50 ranked corporates, Janssen had the highest growth at 26 per cent followed by Allergan at 25.4 per cent and Systopic at 18.8 per cent. Amongst the 51-60 ranked corporates, Boehringer grew at 43.3 per cent followed by Corona at 39.6 per cent and Fresenius Kabi at 37.2 per cent. Amongst the 61-70 ranked corporates, Shreya grew at 25.1 per cent followed by RPG at 15.1 per cent and Serdia at 5.3 per cent. Amongst the 71-80 ranked corporates, Samarth grew at 29.1 per cent followed by Lincoln at 16.9 per cent and Danone at 13.9 per cent. Amongst the 81-90 ranked corporates, Dabur grew at 34.8 per cent followed by Veritaz at 27.7 per cent and Galpha at 27.1 per cent. Amongst the 91- 100 ranked corporates, Ind-Swift grew at 32.5 per cent followed by Curatio at 22.4 per cent and Serum Institute at 20.4 per cent.


The 100th biggest corporate is Curatio and 150th biggest corporate is UTH in the IPM. Wallace as a corporate moved into top 40 as on MAT March 2016.

Indian companies have grown at 7.7 per cent versus two per cent for MNCs in March 2016. Amongst the top 50 in MNCs, Janssen grew at 26 per cent followed by Allergan at 25.4 per cent and Novartis at 14.1 per cent. Under the Non-NLEM category, Indian companies grew at 8.6 per cent whereas MNCs grew at 2.3 per cent.

The NLEM containing molecules market grew at -0.1 per cent whereas the non-DPCO market grew by 7.2 resulting in an overall growth of 6.4 per cent. NLEM and Non-NLEM category showed unit growth of -2.4 per cent and -4.3 per cent respectively.

A total of 12 therapies have outgrown the IPM growth. The respiratory market grew at -4.6 per cent, gastrointestinal grew at 9.3 per cent, pain and analgesics at 4.8 per cent whereas anti-infectives grew at -1.8 per cent. The anti-diabetic market grew at 13.2 per cent and cardiac at 12.2 per cent in chronic business. The derma market grew by 13.3 per cent and urology market at 11 per cent and neuro/ CNS at 13.8 per cent.


A total of 17 regions have outgrown the IPM growth. South Rajasthan market grew the highest at 13.2 per cent followed by Chattisgarh at 12.9 per cent and Haryana at 11.8 per cent. One region had negative growth in March 2016.

The Amoxycillin + Clavulanic acid market grew at -6.1 per cent and Glimepiride + Metformin market grew at 12.7 per cent. The markets of paracetamol grew at 4.7 per cent, Atorvastatin 8.6 per cent, Probiotic Microbes at 29 per cent, Cefixime -10.5 per cent, Pantoprazole 15.1 per cent, Montelukast + Levocetrizine at 0.7 per cent, Glimepiride + Metformin + Pioglitazone at -3.6 per cent, Vitamin-D at 21.1 per cent, Hydroquinone + Mometasone + Tretinoin at -4.5 per cent, Voglibose + Metformin + Glimepiride at 36 per cent, Rosuvastatin at 18.6 per cent, protein supplements at 8.2 per cent, Azithromycin at -12.7 per cent, calcium carbonate + Vit D3 market at 0.4 per cent, Paracetamol + Phenylephrine + Chlorpheniramine at -9.7 per cent, Meropenem at 36 per cent, Montelukast + Fexofenadine at 14.2 per cent, Diclofenac at 18.4 per cent, Telmisartan at 25.5 per cent, Levetiracetam at 27.0 per cent. The 50th biggest market is Cefoperazone + Sulbactam and 100th biggest market is Cefalexin. Mixtard leads the pack with Rs 33 crores followed by Glycomet GP at Rs 28 crores, Lantus & Corex at Rs 26 crores for March 2016.

Few brands who have gained ranks include Meronem (+47), Aciloc RD (+45), Rotarix, Unwanted Kit (+40), Betnovate N (+34), Ultracet (+30), Storvas, Rabipur (+29), Gluconorm-G (+27), Novomix (+23), Rosuvas (+21), Voveran (+20), Rantac (+19), Telma, Istamet, Pantop (+17), Vertin, Cardace (+16), Telma H, Galvus (+14), Synflorix, Electral Powder (+13), Dolonex, Omez, Duphalac (+12), Jalra M, Levipil (+11), Galvus Met, Susten (+10), Aztor, Zoryl M (+8), Lantus, Pan, Thyronorm, Atorva, Allegra (+7), Dolo, Mucaine (+5), amongst top 100 brands over March 2015

Revital H, Lonopin, Razo D, Mero, Metpure XL, Cilacar, Candid, Lobate GM, Orofer S, Enterogermina, Econorm, Pipzo are few brands which have gained ranks in 101-200 ranked brands. A few brands, which have moved up ranks fastest into Top 300 brands are Revital H, Hucog HP, Lonopin, Grafeel, Similac, Candiforce, Diapride M, Razo D. The 300th biggest brand is R-Cinex  from Lupin.

A total of 200 brands and 379 SKUs were launched in March 2016. The top new brands were Gestarest, Ondero Met, Elmonea and Totaglipt M. One brand was launched in Teneligliptin category – Afoglip from Torrent. Within the VMS category, Dhup (Albert David), Bonmax D3 & Bestflow D (Zydus) were launched, within anti-diabetic, Onderomet (Lupin), Afoglip (Torrent), Voglipack M ( Koye), within pain and analgesics category, Adfrar IB (Torrent), Afdiflam D (AFD) & Dolobest MR (TTK), within respiratory, 1 AL M (FDC), Kofcare AM (Unichem), within cardiac, Eritel CH Trio (Eris), Amlodac M (Zydus), Anoxilin (Lincoln) & Rosubest F (Cipla) and within gastro intestinal, Uricure (Emcure), PPTroy D (Troikaa) & Iladac D SR (Zydus). The biggest new launch by an MNC was Dalsiclear in March 2016.

About PharmaTrac

PharmaTrac is a the secondary sales data audit conducted by AIOCD Pharmasofttech AWACS, a pharmaceutical market research company formed by All Indian Origin Chemists & Distributors (AIOCD ) in a joint venture with Trikaal Mediinfotech. AWACS (Advanced Working, Action & Correction System) reflects the underlying philosophy behind AIOCD AWACS’ research tools to reduce time to information by 50 per cent or more and to significantly improve on accuracy of information.

Terminologies used

MAT – Moving Annual Total
MTH – Month
Val (Cr) – Value in Crores
MS per cent – Market Share in Percentage
GR per cent – Growth in percentage.

For more information, visit

Comments are closed.